Company / Total Assets
UroGen Pharma Ltd. Total Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$200.5M
FY2025
5-year range
$119.7M / $285.7M
FY2021-FY2025
Trend
-29.8%
vs FY2024
Sector context
#198 of 214
Health Care
What the data says
Among 214 Health Care companies, UroGen Pharma Ltd. is in the bottom 7% for total assets. Total Assets has fluctuated over the past 9 years, ranging from $76M in FY2017 to $286M in FY2024.
Based on SEC 10-K filings.
$200M in FY2025 with a 5-year CAGR of +10.4%.
Improved from $178M to $200M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- +10.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 214This company $200.5M Sector average $7.5B
▼
-97.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.4%, indicating consistent growth.
- In FY2025, total assets decreased 29.8% year-over-year.
- Ranks #198 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $200.5M | -29.8% |
| FY2024 | $285.7M | +60.2% |
| FY2023 | $178.3M | +31.5% |
| FY2022 | $135.6M | +13.3% |
| FY2021 | $119.7M | -1.9% |
| FY2020 | $122.0M | -39.7% |
| FY2019 | $202.4M | +95.4% |
| FY2018 | $103.6M | +37.1% |
| FY2017 | $75.5M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026